Vitrolife - VTRLY STOCK NEWS

On October 12, 2021, Vitrolife announced the appointment of its election committee members for the 2022 Annual General Meeting. The committee will include Niels Jacobsen from William Demant Invest A/S, Patrik Tigerschiöld from Bure Equity AB, and Wendy Wang from Morgan Stanley Investment Management Inc., with Jón Sigurdsson serving as Chairman. The Annual General Meeting is scheduled for April 27, 2022, in Gothenburg. Shareholders wishing to propose agenda items must submit requests to the Board seven weeks prior to the meeting.

Vitrolife AB has announced an Extraordinary General Meeting (EGM) for shareholders on October 20, 2021, with advance postal voting required. Shareholders must be registered by October 12, 2021, to participate. Key proposals include expanding the Board to six members, an increase in Board remuneration to SEK 2,440,000, and the election of Vesa Koskinen as a new Board member. Additionally, a non-cash issue of shares related to the acquisition of Igenomix will be proposed for approval.

Vitrolife's CFO, Mikael Engblom, has resigned, effective immediately. Engblom, who has served in this role since 2011, will remain until a replacement is found. During his tenure, he significantly contributed to the company's transformation into a market leader in reproductive health, as noted by CEO Thomas Axelsson. Engblom expressed a desire for new challenges after ten years with the company. A recruitment process for a new CFO will commence shortly.

On July 30, 2021, Vitrolife AB announced the issuance of 9,645,303 new shares following a board decision on July 8, 2021. With this issuance, the total number of shares and votes for Vitrolife AB has increased to 118,195,878 as of the announcement date.

Vitrolife AB has completed its share buyback program, repurchasing a total of 52,568 shares from July 15-16, 2021. This initiative was designed to meet obligations related to the long-term incentive program LTIP2021. The buyback was executed under the Market Abuse Regulation and concluded with a total transaction value of SEK 22,822,482 across the two days. Following this buyback, Vitrolife holds 52,568 shares out of a total of 118,195,878 shares outstanding.

On July 15, 2021, Vitrolife reported impressive financial results for Q2 2021 with sales reaching SEK 382 million, an 83% increase. EBITDA rose to SEK 134 million (35% margin), while net income climbed to SEK 86 million (EPS of SEK 0.79). For H1 2021, sales were SEK 761 million, up 40%. The company announced the acquisition of Igenomix for EUR 1.25 billion (about SEK 12.7 billion), marking a strategic expansion.

Vitrolife AB has announced a share buyback program authorized by the Annual General Meeting on April 28, 2021. The program, aimed at securing obligations related to the LTIP 2021, will run from July 15 to August 31, 2021. Up to 52,568 shares can be repurchased at market prices, with payment in cash. Currently, Vitrolife does not hold any own shares.

Vitrolife invites stakeholders to a conference call discussing the interim report for January - June 2021, scheduled for July 15, 2021, at 10:00 a.m. CET. Registration will open 10-15 minutes prior to the call. Participants can dial in via the local Swedish number or the international line, using the conference ID 1295747. The interim report will be made available at 8:00 a.m. CET on the same day. A recorded version of the call will be accessible for seven days thereafter.

Vitrolife's Annual General Meeting on April 28, 2021, confirmed a dividend of SEK 0.80 per share for 2020, with a record date set for April 30, 2021. The meeting re-elected board members, including Jón Sigurdsson as Chairman, and approved total remuneration for the board amounting to SEK 2,165,000. The board received authorization to issue up to 10,850,000 shares and to repurchase shares not exceeding 10% of the total shares. Remuneration principles for senior management were also approved, including a share-based incentive program.